ClinicalTrials.gg
RecruitingNCT07749820Updated Aug 7, 2026

Clinical Trial of Thrombectomy Systems

An interventional study of Peripheral thrombectomy system in Deep Vein Thrombosis (DVT), sponsored by BrosMed Medical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by BrosMed Medical Co., Ltd · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
167
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 59 studies in Venous Thrombosis with a site in China — 16 open to participants now, 18 under way, 2 of them phase 3. Venous Thrombosis · China.

Planned enrollment
26th of 41
167 · median 360
Started
2026
with 1 other
No phase
17 of 59
7 open now
Primary completion
2027-12
later than 12 of 17 live
Registered
58th of 59
by date

Among the 59 studies in Venous Thrombosis with a site in China, this one is the 26th largest by planned enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2026, is one of 17 with no phase, reaches primary completion later than 12 of the 17 other live ones, and was the 58th registered.

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

Browse Venous Thrombosis studies →

Open to participants now

16 of the 59 studies in Venous Thrombosis with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Venous Thrombosis with a site in China, or all of them as a file.
02

Study summary

This study plans to enroll 167 subjects. Subject enrollment and treatment details will be documented, and follow-up assessments will be conducted at screening, on the procedure day, before discharge, and at 1, 3, and 6 months after the procedure, to assess the safety and efficacy of the peripheral thrombectomy system for the treatment of lower extremity deep vein thrombosis.

03

Conditions studied

  • Deep Vein Thrombosis (DVT)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years;
  • Confirmed lower extremity deep vein thrombosis (DVT) by imaging, meeting at least one of the following: (1) acute iliofemoral or femoropopliteal DVT; or (2) subacute iliofemoral DVT;
  • Investigator-assessed ≥1 year;
  • Willing to participate in this study and provide written .

Exclusion criteria

Exclusion Criteria:

  • Infection at the puncture site or severe systemic infection;
  • Inability to establish vascular access or difficulty in advancing the guidewire through the lesion;
  • Hemodynamically unstable pulmonary embolism;
  • The target lesion thrombosis is recurrent after prior interventional therapy;
  • A venous stent has been implanted in the target lesion, or the presence of an inferior vena cava filter that interferes with device deployment;
  • Bilateral lower extremity deep vein thrombosis requiring thrombectomy in the same procedure;
  • Active bleeding within the past 30 days, including severe intracranial, gastrointestinal, or urinary tract bleeding;
  • History of hemorrhagic or ischemic stroke within the past 30 days;
  • Known severe coagulation disorder or bleeding tendency;
  • Severe hepatic or renal impairment;
  • Known allergy or significant to iodine-based contrast media, thrombolytic agents, anticoagulants, or antiplatelet drugs;
  • Known conditions such as severe hyperthyroidism, multiple myeloma, or severe heart failure that preclude tolerance to percutaneous transluminal angioplasty;
  • Pregnant or lactating women, or women planning to become pregnant during the study period;
  • Currently participating in any other clinical trial of a drug or medical device;
  • Any other condition that, in the investigator's judgment, makes the subject ineligible for participation in this trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
167 participants (estimated)

Study arms

  • Experimental
    Test group

    Thrombectomy system

    Device: Peripheral thrombectomy system

Interventions

  • DevicePeripheral thrombectomy system

    For the subjects who met the requirements of the study protocol, the BM peripheral thrombectomy system was used for treatment.

06

What researchers measure

Primary outcomes

  1. Technical success rate

    ≥50% thrombus removal in the target venous segment as assessed by venography.

    Time frame: Immediately after procedure, 0 day

Secondary outcomes

  1. Major adverse events (MAE) rate

    MAE is defined as all-cause death, major bleeding, symptomatic pulmonary embolism, or re-thrombosis of the target venous segment.

    Time frame: 30 days

  2. Device success rate

    Device success is defined as successful delivery of the thrombectomy catheter to the target lesion, smooth deployment during the procedure, and removal.

    Time frame: Immediately after procedure, 0 day

  3. VCSS score

    The number of patients that have improvement in Venous Clinical Severity Score (VCSS) which is a clinical assessment by the physician to score patient reported symptoms from a score of 0 to 3 based on severity. A score of 0 indicates absence of symptoms and a score of 3 indicates severe symptoms. The total score is the sum of all individual scores.

    Time frame: Baseline, 1 Month, 6 Months

  4. Vein Patency

    The number of patients who have vein patency as measured by duplex ultrasound, CTV, or DSA.

    Time frame: at 6 months

  5. Incidence of PTS

    Assessed by the Villalta score, patients with a score of ≥5 points are diagnosed with post-thrombotic syndrome (PTS).

    Time frame: at 6 Months

  6. AE and SAE

    Occurrence of adverse events (AE) and serious adverse events (SAE) during the study.

    Time frame: Up to 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Dec 2027, 16 months later.

Of 117 interventional studies with no phase under Venous Thrombosis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 56. This study's planned 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2026
First posted
Aug 6, 2026
StartEst.
Aug 30, 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07749820
Responsible party
Sponsor
First posted
Aug 6, 2026
Start date
Aug 30, 2026 (estimated)
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Aug 7, 2026

Study contacts

Fu, PhD
Contact
fu.weiguo@zs-hospital.sh.cn
021-31587871

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion